Literature DB >> 28548126

MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer.

Eva Karamitopoulou1, Stefan Haemmig2, Ulrich Baumgartner2, Cornelia Schlup2, Martin Wartenberg1, Erik Vassella2.   

Abstract

Cellular interactions in the tumor microenvironment influence neoplastic progression in pancreatic ductal adenocarcinoma. One underlying mechanism is the induction of the prognostically unfavorable epithelial-mesenchymal-transition-like tumor budding. Our aim is to explore the expression of microRNAs implicated in the regulation of tumor budding focusing on the microenvironment of the invasive front. To this end, RNA from laser-capture-microdissected material of the main tumor, tumor buds, juxta-tumoral stroma, tumor-remote stroma, and non-neoplastic pancreatic parenchyma from pancreatic cancer cases with (n=7) and without (n=6) tumor budding was analyzed by qRT-PCR for the expression of a panel of miRNAs that are known to be implicated in the regulation of epithelial-mesenchymal transition, including miR-21, miR-183, miR-200b, miR-200c, miR-203, miR-205, miR-210, and miR-217. Here we show that at the invasive front of pancreatic ductal adenocarcinoma, specific microRNAs, are differentially expressed between tumor buds and main tumor cells and between cases with and without tumor budding, indicating their involvement in the regulation of the budding phenotype. Notably, miR-200b and miR-200c were significantly downregulated in the tumor buds. Consistent with this finding, they negatively correlated with the expression of epithelial-mesenchymal-transition-associated E-cadherin repressors ZEB1 and ZEB2 in the budding cells (P<0.001). Interestingly, many microRNAs were also dysregulated in juxta-tumoral compared to tumor-remote stroma suggesting that juxta-tumoral stroma contributes to microRNA dysregulation. Notably, miR-200b and miR-200c were strongly downregulated while miR-210 and miR-21 were upregulated in the juxta-tumoral vs tumor-remote stroma in carcinomas with tumor budding. In conclusion, microRNA targeting in both tumor and stromal cells could represent a treatment option for aggressive pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28548126     DOI: 10.1038/modpathol.2017.35

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  52 in total

1.  microRNA-21 mediates epithelial-mesenchymal transition of human hepatocytes via PTEN/Akt pathway.

Authors:  Zhenyu Liu; Jingjie Wang; Chuanyong Guo; Xiaoming Fan
Journal:  Biomed Pharmacother       Date:  2014-11-06       Impact factor: 6.529

2.  PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.

Authors:  Martin Wartenberg; Irene Centeno; Stefan Haemmig; Erik Vassella; Inti Zlobec; José A Galván; Maja Neuenschwander; Cornelia Schlup; Beat Gloor; Alessandro Lugli; Aurel Perren; Eva Karamitopoulou
Journal:  Eur J Cancer       Date:  2016-07-29       Impact factor: 9.162

3.  Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6.

Authors:  Jörg Fellenberg; Heiner Sähr; Pierre Kunz; Zhefu Zhao; Li Liu; Diana Tichy; Ingrid Herr
Journal:  Cancer Lett       Date:  2015-11-30       Impact factor: 8.679

4.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.

Authors:  Cameron P Bracken; Philip A Gregory; Natasha Kolesnikoff; Andrew G Bert; Jun Wang; M Frances Shannon; Gregory J Goodall
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator.

Authors:  Aihong Jiao; Minghua Sui; Liangming Zhang; Ping Sun; Dongmei Geng; Weiwei Zhang; Xiuwen Wang; Junxia Li
Journal:  Mol Med Rep       Date:  2016-02-17       Impact factor: 2.952

6.  miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian Cancer.

Authors:  Guannan Zhao; Yuqi Guo; Zixuan Chen; Yinan Wang; Chuanhe Yang; Andrew Dudas; Ziyun Du; Wen Liu; Yanan Zou; Erzsebet Szabo; Sue-Chin Lee; Michelle Sims; Weiwang Gu; Todd Tillmanns; Lawrence M Pfeffer; Gabor Tigyi; Junming Yue
Journal:  J Cancer Sci Ther       Date:  2015

7.  MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.

Authors:  Adam E Frampton; Leandro Castellano; Teresa Colombo; Elisa Giovannetti; Jonathan Krell; Jimmy Jacob; Loredana Pellegrino; Laura Roca-Alonso; Niccola Funel; Tamara M H Gall; Alexander De Giorgio; Filipa G Pinho; Valerio Fulci; David J Britton; Raida Ahmad; Nagy A Habib; R Charles Coombes; Victoria Harding; Thomas Knösel; Justin Stebbing; Long R Jiao
Journal:  Gastroenterology       Date:  2013-10-09       Impact factor: 22.682

8.  miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.

Authors:  Nora Bandi; Erik Vassella
Journal:  Mol Cancer       Date:  2011-05-16       Impact factor: 27.401

9.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.

Authors:  Ulrike Burk; Jörg Schubert; Ulrich Wellner; Otto Schmalhofer; Elizabeth Vincan; Simone Spaderna; Thomas Brabletz
Journal:  EMBO Rep       Date:  2008-05-16       Impact factor: 8.807

Review 10.  The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy.

Authors:  Brock Humphries; Chengfeng Yang
Journal:  Oncotarget       Date:  2015-03-30
View more
  14 in total

Review 1.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

Review 2.  Drivers of Gene Expression Dysregulation in Pancreatic Cancer.

Authors:  Swati Venkat; Abdulrahman A Alahmari; Michael E Feigin
Journal:  Trends Cancer       Date:  2021-02-19

3.  Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.

Authors:  Jukun Song; Qiuyan Xu; Haodeng Zhang; Xinhai Yin; Chen Zhu; Ke Zhao; Jianguo Zhu
Journal:  J Cell Biochem       Date:  2018-02-27       Impact factor: 4.429

Review 4.  Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features.

Authors:  Eva Karamitopoulou
Journal:  Br J Cancer       Date:  2019-05-21       Impact factor: 7.640

Review 5.  Role of non-coding RNA in pancreatic cancer.

Authors:  Yinghao Lv; Shuai Huang
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

Review 6.  Cell Cycle Regulation of Stem Cells by MicroRNAs.

Authors:  Michelle M J Mens; Mohsen Ghanbari
Journal:  Stem Cell Rev Rep       Date:  2018-06       Impact factor: 5.739

7.  MiR-4269 suppresses the tumorigenesis and development of pancreatic cancer by targeting ZEB1/OTX1 pathway.

Authors:  Xin Sui; Zhenghui Sui
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

Review 8.  miRNAs as Influencers of Cell-Cell Communication in Tumor Microenvironment.

Authors:  Ilaria Conti; Gabriele Varano; Carolina Simioni; Ilaria Laface; Daniela Milani; Erika Rimondi; Luca M Neri
Journal:  Cells       Date:  2020-01-15       Impact factor: 6.600

9.  FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer.

Authors:  Hsi-Hsien Hsu; Wei-Wen Kuo; Hui-Nung Shih; Sue-Fei Cheng; Ching-Kuo Yang; Ming-Cheng Chen; Chuan-Chou Tu; Vijaya Padma Viswanadha; Po-Hsiang Liao; Chih-Yang Huang
Journal:  Cancers (Basel)       Date:  2019-10-16       Impact factor: 6.639

10.  A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection.

Authors:  Adam R Wolfe; Patrick Wald; Amy Webb; Nikhil Sebastian; Steve Walston; Ryan Robb; Wei Chen; Marall Vedaie; Mary Dillhoff; Wendy L Frankel; Wooil Kwon; Jin-Young Jang; Terence M Williams
Journal:  Oncotarget       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.